Home › Pancreatic Cancer › Illinois › Galesburg
Pancreatic Cancer clinical trials in Galesburg, IL
4 studies for Pancreatic Cancer are looking for participants at sites in and around Galesburg (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
RecruitingObservational study
- Illinois CancerCare-Galesburg, Galesburg
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
RecruitingPhase 3
- Illinois CancerCare-Galesburg, Galesburg
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
RecruitingPhase 3
- Illinois CancerCare-Galesburg, Galesburg
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
RecruitingObservational study
- Illinois CancerCare-Galesburg, Galesburg
About Pancreatic Cancer
The pancreas is a gland behind your stomach that produces insulin. Pancreatic cancer is hard to catch early. Find out about risk factors and symptoms.
More about Pancreatic Cancer on MedlinePlus
Pancreatic Cancer trials in other cities
- Houston, TX61 studies
- New York City, NY60 studies
- Boston, MA43 studies
- Nashville, TN39 studies
- Los Angeles, CA35 studies
- St. Louis, MO33 studies
- Arlington, VA33 studies
- Baltimore, MD31 studies
- San Antonio, TX31 studies
- Philadelphia, PA26 studies
- Tampa, FL26 studies
- Durham, NC24 studies
Other studies in Galesburg
- Non-Small Cell Lung Cancer11 studies
- Lung Cancer9 studies
- Colorectal Cancer7 studies
- Prostate Cancer6 studies
- Breast Cancer5 studies
- Head and Neck Squamous Cell Carcinoma5 studies
- Acute Myeloid Leukemia4 studies
- Colon Cancer4 studies
- Melanoma4 studies
- Hypopharyngeal Cancer4 studies
- Laryngeal Cancer4 studies
- Oral Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.